Your AI-Trained Oncology Knowledge Connection!
Jason Mouabbi, MD, is an assistant professor in the Department of Breast Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
Panelists discuss how emerging data from studies like E-BLIS and I-SPY 2 validate circulating tumor DNA (ctDNA) as a powerful prognostic tool in early breast cancer, showing it can detect recurrence months before imaging and potentially refine risk stratification beyond traditional markers, though its role in guiding treatment decisions remains under active investigation.
Panelists discuss how circulating tumor DNA (ctDNA) monitoring provides a valuable lead time for detecting recurrence in early-stage breast cancer—especially hormone receptor–positive cases—yet requires careful patient counseling and integration with traditional prognostic tools, as its use for guiding treatment decisions remains nuanced and dependent on evolving clinical evidence.
Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.
A panelist discusses how combination studies like ELEVATE are exploring elacestrant with other targeted therapies, showing promising results with ribociclib and everolimus combinations that are well-tolerated and efficacious.
A panelist discusses how real-world studies of elacestrant showed even better outcomes than clinical trials, with progression-free survival approaching 9 months, demonstrating the drug’s effectiveness in broader patient populations.
Panelists discuss how circulating tumor DNA (ctDNA) testing for molecular residual disease (MRD) offers a sensitive tool for detecting early breast cancer recurrence before clinical symptoms appear while emphasizing the importance of shared decision-making, patient education, and clinical trial referral in the absence of standardized guidelines for managing ctDNA-positive results.
Panelists discuss how current breast cancer surveillance remains largely symptom-driven and reactive, often missing early metastatic recurrence, and how circulating tumor DNA (ctDNA) testing offers a promising shift toward proactive, personalized monitoring by enabling earlier detection of molecular residual disease (MRD) and guiding timely therapeutic interventions.
A panelist discusses how elacestrant should be used as soon as ESR1 mutations emerge, emphasizing that it works equally well in visceral and bone metastases and that ESR1 mutations must be targeted before other mutations due to their resistance-driving nature.
A panelist discusses how the landmark EMERALD study established elacestrant as an effective treatment for heavily pretreated patients with ESR1 mutations, showing 8 to 9 months median progression-free survival versus less than 2 months with standard care.
A panelist discusses how the SERENA-6 study presented at ASCO 2025 showed that switching therapy early based on molecular progression (ESR1 mutation emergence) before radiological progression improved outcomes, with a 60% reduction in risk.
A panelist discusses how testing for ESR1 mutations should be performed after every progression using liquid biopsies and how elacestrant is currently the only approved oral SERD that effectively targets these mutations.
Jason A. Mouabbi, MD, discusses how ESR1 mutations can cause patients with HR-positive, HER2-negative breast cancer to develop endocrine resistance.
Jason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma
Jason A. Mouabbi, MD, discusses clinical trials aimed at expanding the treatment paradigm for invasive lobular breast cancer.
Jason Abdou Mouabbi, MD, discusses considerations for the use of ribociclib vs abemaciclib in patients with HR-positive, HER2-negative breast cancer.
